中华骨质疏松和骨矿盐疾病杂志
中華骨質疏鬆和骨礦鹽疾病雜誌
중화골질소송화골광염질병잡지
Chinese Journal of Osteoporosis and Bone Mineral Research
2015年
3期
256-260
,共5页
降糖药物%成骨细胞%破骨细胞%骨密度
降糖藥物%成骨細胞%破骨細胞%骨密度
강당약물%성골세포%파골세포%골밀도
antidiabetic medicine%osteoblast%osteoclast%bone mineral density
糖尿病和骨质疏松关系复杂，糖尿病类型、慢性并发症如血管病变和肾脏病变可能影响骨代谢，降糖药对骨代谢也有一定影响。二甲双胍、胰岛素和胰高血糖素-1（glucagon-like peptide-1， GLP-1）能增加骨密度，促进骨形成。而噻唑烷二酮类能降低骨密度，抑制骨形成。磺脲类药物及二肽基肽酶Ⅳ（ dipep-tidyl peptidase Ⅳ， DPP-4）抑制剂对骨代谢的影响暂无定论，尚需更多的研究证实。本文就降糖药对骨代谢影响的研究进展作一综述。
糖尿病和骨質疏鬆關繫複雜，糖尿病類型、慢性併髮癥如血管病變和腎髒病變可能影響骨代謝，降糖藥對骨代謝也有一定影響。二甲雙胍、胰島素和胰高血糖素-1（glucagon-like peptide-1， GLP-1）能增加骨密度，促進骨形成。而噻唑烷二酮類能降低骨密度，抑製骨形成。磺脲類藥物及二肽基肽酶Ⅳ（ dipep-tidyl peptidase Ⅳ， DPP-4）抑製劑對骨代謝的影響暫無定論，尚需更多的研究證實。本文就降糖藥對骨代謝影響的研究進展作一綜述。
당뇨병화골질소송관계복잡，당뇨병류형、만성병발증여혈관병변화신장병변가능영향골대사，강당약대골대사야유일정영향。이갑쌍고、이도소화이고혈당소-1（glucagon-like peptide-1， GLP-1）능증가골밀도，촉진골형성。이새서완이동류능강저골밀도，억제골형성。광뇨류약물급이태기태매Ⅳ（ dipep-tidyl peptidase Ⅳ， DPP-4）억제제대골대사적영향잠무정론，상수경다적연구증실。본문취강당약대골대사영향적연구진전작일종술。
The diabetes and osteoporosis have complicated relationship with each other .The type of diabetes , chronic complications of diabetes such as vascular lesions and kidney disease may have effects on bone metabolism , so may be the antidiabetic medicines .Metformin, insulin and glucagon-like peptide-1 ( GLP-1) can increase bone density , and promote bone formation .But thiazolidinedione ( TZD ) can reduce bone density and inhibit bone formation .The effects of sulfonylurea and dipeptidyl peptidase Ⅳ (DPP-4) inhibitors on the bone metabolism are uncertain , and more researches are needed .We review the progress of effects of antdiabetic medicine on bone metabolism .
